全文获取类型
收费全文 | 163237篇 |
免费 | 12139篇 |
国内免费 | 312篇 |
学科分类
医药卫生 | 175688篇 |
出版年
2023年 | 591篇 |
2022年 | 604篇 |
2021年 | 2443篇 |
2020年 | 1739篇 |
2019年 | 2583篇 |
2018年 | 3225篇 |
2017年 | 2674篇 |
2016年 | 2920篇 |
2015年 | 3309篇 |
2014年 | 4551篇 |
2013年 | 6173篇 |
2012年 | 9382篇 |
2011年 | 9649篇 |
2010年 | 5118篇 |
2009年 | 5352篇 |
2008年 | 8656篇 |
2007年 | 8969篇 |
2006年 | 8750篇 |
2005年 | 8465篇 |
2004年 | 7354篇 |
2003年 | 6985篇 |
2002年 | 6505篇 |
2001年 | 5261篇 |
2000年 | 5170篇 |
1999年 | 4712篇 |
1998年 | 2153篇 |
1997年 | 1804篇 |
1996年 | 1818篇 |
1995年 | 1539篇 |
1994年 | 1445篇 |
1993年 | 1299篇 |
1992年 | 3261篇 |
1991年 | 3009篇 |
1990年 | 2813篇 |
1989年 | 2631篇 |
1988年 | 2395篇 |
1987年 | 2127篇 |
1986年 | 2050篇 |
1985年 | 1961篇 |
1984年 | 1471篇 |
1983年 | 1287篇 |
1982年 | 808篇 |
1981年 | 762篇 |
1980年 | 626篇 |
1979年 | 1099篇 |
1978年 | 725篇 |
1977年 | 650篇 |
1974年 | 619篇 |
1973年 | 580篇 |
1972年 | 530篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
2.
3.
4.
5.
Whitney S. Brandt Wanpu Yan Jian Zhou Kay See Tan Joseph Montecalvo Bernard J. Park Prasad S. Adusumilli James Huang Matthew J. Bott Valerie W. Rusch Daniela Molena William D. Travis Mark G. Kris Jamie E. Chaft David R. Jones 《The Journal of thoracic and cardiovascular surgery》2019,157(2):743-753.e3
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献6.
7.
8.
9.
10.
Interprofessional collaboration and communication in nursing homes: a qualitative exploration of problems in medical care for nursing home residents – study protocol 下载免费PDF全文